On Monday, Shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN), lost -2.03% to $2.41.
Amarin Corporation plc, declared that John F. Thero, Amarin’s President and Chief Executive Officer, presented a general company update at the Rodman & Renshaw 2015 Global Investment Conference in New York City on Wednesday, September 9, 2015, at 4:40 p.m. ET.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
Shares of Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC), declined -0.45% to $8.78, during its last trading session.
Integrated communication and technology services provider Turkcell marked its 15th year as a publicly-traded company as it rang the Closing Bell on the New York Stock Exchange (NYSE). Mr. Ahmet Akca, Chairman of the Turkcell Board of Directors, and Mr Kaan Terzioglu, Turkcell’s CEO, were joined by members of the Turkcell Board, NYSE President Tom Farley, Turkey’s Consul-General in New York Mr. Ertan Yalcin, representatives of Turkcell’s shareholders and Turkcell’s upper administration as they rang the Closing Bell.
Turkcell is the first company from Turkey to be listed on the NYSE. It has a current valuation of more than 10 billion USD and is among the 500 largest NYSE-listed companies, in terms of market capitalization.
“The NYSE listing has made it possible for Turkcell to access the world’s largest capital market. Our listing on the NYSE also assisted initiate a new era for Turkish business community as we demonstrated that a Turkish company could provide attractive investment opportunities for international investors,” said Ahmet Akca, the Chairman of the Turkcell Board. “Over the past 15 years, we have adopted high corporate governance standards while operating a profitable business. Turkcell will continue to aim for the highest aims in technology, contribute to the growth of the countries where it operates, and create value for all its stakeholders.”
Turkcell Iletisim Hizmetleri AS establishes and operates a Global System for Mobile Communications (GSM) network in Turkey and regional states. It operates in four segments: Turkcell, Euroasia, Belarusian Telecom, and Superonline.
Finally, RXi Pharmaceuticals Corp (NASDAQ:RXII), ended its last trade with -1.10% loss, and closed at $0.485.
RXi Pharmaceuticals Corporation, declared that it has been granted a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the methods of use of siRNA sequences targeting vascular endothelial growth factor (VEGF). The patent, part of RXi’s attained OPKO estate, is planned to expire in 2022 and may become eligible for Patent Term Extension (PTE) subject to certain conditions being met.
RNAi compounds targeting these VEGF sequences may be beneficial for the treatment of neovascularization disorders, counting wet age-related macular degeneration (AMD) and diabetic retinopathy. RNAi compounds targeting these sequences also have the potential to be useful in combination with RXI-109 which could address both the neovascularization and scarring components encountered in AMD.
“This Notice of Allowance from the USPTO for these sequences expands and strengthens our intellectual property estate in the anti-VEGF area, which comprises ophthalmology, one of our seven core initiatives to improvement shareholder value,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He further added, “With the recent activation of our ophthalmology IND, and with this Notice of Allowance, we not only improvement the value proposition of our Ophthalmology Franchise for our shareholders and potential business partners, we also expand and improve our intellectual property position for planned partnering of our self-delivering technology platform in other therapeutic areas.”
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
